drugset / Trial / NCT01315847

Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067)

NCT01315847

Phase 1 Completed 10 enrolled Merck Sharp & Dohme LLC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the receptor occupancy (RO) associated with telcagepant (MK-0974) administration based on displacement of \[11C\]MK-4232 from the CGRP receptors in the brain using PET. The study enrolled healthy participants (Part I) and migraine patients (Part III). Due to a protocol amendment, study Part II was not conducted.

Timeline

Start
2010-01-14
Primary completion
2011-07-26
Completion
2011-07-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Telcagepant Small molecule 140 mg Oral
Subject Telcagepant Small molecule 1120 mg Oral

Indications